#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Idiopathic pulmonary fibrosis Myelodysplastic syndrome Diffuse large B-cell lymphoma refractory Immunodeficiency Dermatitis Neuroendocrine tumour of the lung Chronic kidney disease Hypersomnia Bronchopulmonary aspergillosis Prolymphocytic leukaemia Chronic hepatitis B Netherton's syndrome Mucopolysaccharidosis III Extra-osseous Ewing's sarcoma recurrent Thyroid cancer metastatic More trials…

    Learn about Rare Diseases

    Hyperoxaluria – Treatment Pulmonary fibrosis – Diagnostics Von Willebrand’s disease – Life with Disease Pituitary-dependent Cushing’s syndrome – Diagnostics Loeys-Dietz syndrome – Trials in Disease Cystic fibrosis – Diagnostics Ewing’s sarcoma Osteosarcoma metastatic – Basic Information Thrombotic thrombocytopenic purpura – Treatment Mucopolysaccharidosis – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ht-29-B Mirabegron Flutafuranol (18F) Insulin Human (Rdna) Tioguanine Blinatumomab Avalotcagene Ontaparvovec Netupitant Nilutamide Solifenacin Succinate Gelatin Andexanet Alfa Fulvestrant Rotigotine Cefepime Hydrochloride Teicoplanin RUBIDIUM CHLORIDE Lumateperone Remifentanil Hydrochloride Protrans More therapies…

    Learn about Your Condition

    Keratosis follicular C3 glomerulopathy Major depression Strongyloidiasis Skin neoplasm excision Constipation Prostate cancer Biliary tract operation Kaposi's sarcoma Papulopustular rosacea Follicular thyroid cancer Childhood asthma Food allergy Cortisol abnormal Seizure More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. University Of Debrecen

University Of Debrecen

Mxgmyw Zoewyprc Kkikc 2or Dekfwvixv 4evnk Hbmjuvv

Want to learn more about this study or check if you can participate? Contact us.

  • Study on the Effects of Human Normal Immunoglobulin in Adults with Dermatomyositis

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Human Normal Immunoglobulin
    Belgium France Germany Hungary Italy Poland +1

  • Study of resmetirom (MGL-3196) in patients with Non-Alcoholic Steatohepatitis (NASH) to prevent liver damage and disease progression

    Not recruiting

    3 1
    Investigated Drugs:
    • Resmetirom
    Austria Belgium France Germany Hungary Italy +2

  • Study on the Safety and Effectiveness of Cenobamate for Children with Focal Seizures

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Partial seizures
    Investigated Drugs:
    • Cenobamate
    Germany Hungary Poland Spain

  • Study on the Safety and Effectiveness of TIN816 for Patients with Sepsis-Related Acute Kidney Injury

    Not recruiting

    2 1
    Investigated Diseases:
    • Acute kidney injury
    • Sepsis
    Investigated Drugs:
    • Tin816
    Austria Belgium Czechia France Germany Hungary +2

  • Study on the Effectiveness of Ianalumab for Treating Moderate to Severe Hidradenitis Suppurativa in Patients

    Not recruiting

    2 1
    Investigated Diseases:
    • Hidradenitis
    Investigated Drugs:
    • Ianalumab
    Austria Belgium France Germany Hungary Spain

  • Study Comparing Asciminib with Other Drug Combinations for Adults with Newly Diagnosed Chronic Myeloid Leukemia

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Chronic myeloid leukaemia
    Investigated Drugs:
    • Bosutinib
    • Dasatinib
    • Nilotinib
    Austria Belgium Bulgaria Czechia Denmark Finland +9

  • Study on the Safety and Effectiveness of Nirmatrelvir and Ritonavir for Nonhospitalized Children with COVID-19 at Risk of Severe Illness

    Not recruiting

    4 1 1
    Investigated Diseases:
    • COVID-19
    Investigated Drugs:
    • Nirmatrelvir
    • Ritonavir
    Bulgaria Hungary

  • Study on the Safety and Effectiveness of Betula Pollen Extract for Children and Adolescents Aged 5-17 with Birch Pollen Allergies and Possible Asthma

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Conjunctivitis allergic
    Investigated Drugs:
    • Betula Pollen Extract
    Austria Bulgaria Finland France Germany Hungary +6

  • Study on Anifrolumab for Adults with Active Lupus Nephritis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Lupus nephritis
    Investigated Drugs:
    • Anifrolumab
    Belgium Bulgaria France Germany Hungary Italy +2

  • Study on Long-Term Safety and Effectiveness of Abrocitinib for Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Abrocitinib
    Hungary Poland Spain
Previous Page
1 … 36 37 38 39 40 … 52
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!